Skip to main content

25.07.2017 | Original Article | Ausgabe 1/2018

Supportive Care in Cancer 1/2018

A randomized phase II trial of geriatric assessment and management for older cancer patients

Supportive Care in Cancer > Ausgabe 1/2018
Martine T. E. Puts, Schroder Sattar, Michael Kulik, Mary Ellen MacDonald, Kara McWatters, Katherine Lee, Sarah Brennenstuhl, Raymond Jang, Eitan Amir, Monika K. Krzyzanowska, Anthony M. Joshua, Johanne Monette, Doreen Wan-Chow-Wah, Shabbir M. H. Alibhai
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00520-017-3820-7) contains supplementary material, which is available to authorized users.



Geriatric assessment and management (GAM) can identify current health issues and recommend interventions to optimize well-being of older adults, but no randomized trial has yet been completed in oncology. Therefore, a randomized phase 2 trial was conducted.


A two-group parallel single-blinded randomized phase II trial (ClinicalTrials.​gov Identifier: NCT02222259) enrolled patients aged ≥70 years, diagnosed with stage 2–4 gastrointestinal, genitourinary, or breast cancer within 6 weeks of commencing chemotherapy at Princess Margaret Cancer Centre. The coprimary feasibility outcomes were the proportion of eligible patients enrolled and retained. The coprimary clinical outcomes were quality of life (QOL) (EORTC QLQ C30) and modification of cancer treatment. Descriptive and regression analyses using intent-to-treat analysis were conducted.


Sixty-one persons (64%) agreed to participate (31 allocated to intervention arm and 30 to control group). In the control group, more participants died and refused follow-up. The benefit of intervention over control on QOL at 3 months was greater for those who survived 6 months (difference 9.28; 95% CI −10.35 to 28.91) versus those who survived only 3 months (difference 6.55; 95% CI −9.63 to 22.73).


This trial showed that it was feasible to recruit and retain older adults for a GAM study. Those who survived at least 6 months seemed to receive a greater QOL benefit than those who died or withdrew.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Supportive Care in Cancer 1/2018Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.